PL1715890T3 - CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową - Google Patents
CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycowąInfo
- Publication number
- PL1715890T3 PL1715890T3 PL05713358T PL05713358T PL1715890T3 PL 1715890 T3 PL1715890 T3 PL 1715890T3 PL 05713358 T PL05713358 T PL 05713358T PL 05713358 T PL05713358 T PL 05713358T PL 1715890 T3 PL1715890 T3 PL 1715890T3
- Authority
- PL
- Poland
- Prior art keywords
- diabetic nephropathy
- microalbuminuria
- ctgf
- therapy
- patients
- Prior art date
Links
- 208000007342 Diabetic Nephropathies Diseases 0.000 title abstract 3
- 208000033679 diabetic kidney disease Diseases 0.000 title abstract 3
- 101150091877 Ccn2 gene Proteins 0.000 title 1
- 206010027525 Microalbuminuria Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54412104P | 2004-02-11 | 2004-02-11 | |
| US56101804P | 2004-04-08 | 2004-04-08 | |
| US57840104P | 2004-06-09 | 2004-06-09 | |
| US62080204P | 2004-10-20 | 2004-10-20 | |
| EP05713358A EP1715890B1 (en) | 2004-02-11 | 2005-02-11 | Ctgf as target for the therapy of microalbuminuria in patients with diabetic nephropathy |
| PCT/US2005/004367 WO2005077413A1 (en) | 2004-02-11 | 2005-02-11 | Ctgf as target for the therapy of diabetic nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1715890T3 true PL1715890T3 (pl) | 2009-01-30 |
Family
ID=34865408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05713358T PL1715890T3 (pl) | 2004-02-11 | 2005-02-11 | CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20050214294A1 (pl) |
| EP (2) | EP1977762A1 (pl) |
| CN (1) | CN101884789A (pl) |
| AT (1) | ATE400297T1 (pl) |
| AU (1) | AU2005212371B2 (pl) |
| CA (1) | CA2555789A1 (pl) |
| DE (1) | DE602005008013D1 (pl) |
| DK (1) | DK1715890T3 (pl) |
| ES (1) | ES2311973T3 (pl) |
| IL (1) | IL177437A (pl) |
| NZ (1) | NZ549784A (pl) |
| PL (1) | PL1715890T3 (pl) |
| PT (1) | PT1715890E (pl) |
| WO (1) | WO2005077413A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1038318A1 (zh) * | 1998-09-08 | 2002-03-15 | Henry Ford Health System | 透过缓和、调节及抑制连接组织生长因子而测定、预防及治疗肾失调症 |
| AU2006244147A1 (en) | 2005-05-05 | 2006-11-16 | Fibrogen, Inc. | Vascular disease therapies |
| ATE481094T1 (de) * | 2005-12-22 | 2010-10-15 | Kiacta Sarl | Behandlung von diabetischer nephropathie |
| JP2010529947A (ja) * | 2006-12-22 | 2010-09-02 | ベラス ヘルス（インターナショナル）リミテッド | 代謝性疾患および糖尿病を治療するための方法、化合物、および組成物 |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| CN103429270B (zh) | 2008-08-25 | 2016-11-23 | 埃克斯雷德制药有限公司 | 阻止结缔组织生长因子的反义核苷酸及其用途 |
| US9173894B2 (en) | 2011-02-02 | 2015-11-03 | Excaliard Pharamaceuticals, Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF) |
| CA2931357C (en) | 2013-11-28 | 2022-07-12 | Csl Limited | Method of treating nephropathy |
| WO2019032746A1 (en) | 2017-08-08 | 2019-02-14 | Fresenius Medical Care Holdings, Inc. | SYSTEMS AND METHODS FOR TREATING AND ESTIMATING THE PROGRESSION OF CHRONIC RENAL DISEASE |
| CN112512532B (zh) * | 2018-07-31 | 2024-11-08 | 雷莫内克斯生物制药有限公司 | 用于抑制ctgf表达的组合物 |
| CN109402127B (zh) * | 2018-09-29 | 2021-12-10 | 复旦大学附属眼耳鼻喉科医院 | 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用 |
| CN109453191A (zh) * | 2018-12-06 | 2019-03-12 | 郑州大学第附属医院 | GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用 |
| AU2020289303A1 (en) * | 2019-06-04 | 2022-01-27 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-connective tissue growth factor antibody and application thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408040A (en) * | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
| US5770209A (en) | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
| US5876730A (en) | 1997-08-07 | 1999-03-02 | Childrens Hospital Research Foundation | Heparin-binding growth factor (HBGF) polypeptides |
| AU1682699A (en) | 1997-12-25 | 1999-07-19 | Japan Tobacco Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| US20010006979A1 (en) | 1998-07-08 | 2001-07-05 | Richard Stratton | Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives |
| HK1038318A1 (zh) * | 1998-09-08 | 2002-03-15 | Henry Ford Health System | 透过缓和、调节及抑制连接组织生长因子而测定、预防及治疗肾失调症 |
| CA2350182A1 (en) | 1998-11-06 | 2000-05-18 | Fibrogen, Inc. | Connective tissue growth factor (ctgf) and methods of use |
| US6348329B1 (en) * | 1998-11-06 | 2002-02-19 | Fibrogen, Inc. | Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use |
| EP1140964B1 (en) | 1998-12-14 | 2008-04-09 | University Of Miami | Connective tissue growth factor (ctgf) fragment |
| US6706491B1 (en) | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| US20030153524A1 (en) * | 2001-12-11 | 2003-08-14 | Hinton David R. | Methods for inhibiting ocular processes |
| EP1497420A4 (en) | 2002-04-30 | 2005-04-27 | Alcon Inc | AGENTS THAT REGULATE, RESTRICT OR MODULATE THE ACTIVITY AND / OR EXPRESSION OF BIND WEAVE GROWTH FACTOR (CTGF) AS UNIQUE MEDICAMENTS BOTH TO REDUCE EYESPRINTS AND TREAT GLACCOMPETOSIS RETINOPATHIES / OPTIC NEUROPATHIES |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| EP1687410A4 (en) | 2003-10-07 | 2008-04-09 | Isis Pharmaceuticals Inc | ANTISENSE OLIGONUCLEOTIDE OPTIMIZED FOR KIDNEY TARGETING |
-
2005
- 2005-02-11 US US11/057,323 patent/US20050214294A1/en not_active Abandoned
- 2005-02-11 PL PL05713358T patent/PL1715890T3/pl unknown
- 2005-02-11 WO PCT/US2005/004367 patent/WO2005077413A1/en not_active Ceased
- 2005-02-11 PT PT05713358T patent/PT1715890E/pt unknown
- 2005-02-11 NZ NZ549784A patent/NZ549784A/en unknown
- 2005-02-11 EP EP08011905A patent/EP1977762A1/en not_active Withdrawn
- 2005-02-11 AT AT05713358T patent/ATE400297T1/de active
- 2005-02-11 AU AU2005212371A patent/AU2005212371B2/en not_active Ceased
- 2005-02-11 DK DK05713358T patent/DK1715890T3/da active
- 2005-02-11 DE DE602005008013T patent/DE602005008013D1/de not_active Expired - Lifetime
- 2005-02-11 CN CN2010102312546A patent/CN101884789A/zh active Pending
- 2005-02-11 EP EP05713358A patent/EP1715890B1/en not_active Expired - Lifetime
- 2005-02-11 CA CA002555789A patent/CA2555789A1/en not_active Abandoned
- 2005-02-11 ES ES05713358T patent/ES2311973T3/es not_active Expired - Lifetime
-
2006
- 2006-08-10 IL IL177437A patent/IL177437A/en active IP Right Grant
-
2010
- 2010-06-03 US US12/802,373 patent/US8314059B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2555789A1 (en) | 2005-08-25 |
| US20050214294A1 (en) | 2005-09-29 |
| ES2311973T3 (es) | 2009-02-16 |
| EP1715890A1 (en) | 2006-11-02 |
| IL177437A0 (en) | 2006-12-10 |
| PT1715890E (pt) | 2008-10-17 |
| NZ549784A (en) | 2008-06-30 |
| AU2005212371A1 (en) | 2005-08-25 |
| EP1977762A1 (en) | 2008-10-08 |
| US8314059B2 (en) | 2012-11-20 |
| ATE400297T1 (de) | 2008-07-15 |
| DE602005008013D1 (de) | 2008-08-21 |
| EP1715890B1 (en) | 2008-07-09 |
| WO2005077413A1 (en) | 2005-08-25 |
| US20100291098A1 (en) | 2010-11-18 |
| IL177437A (en) | 2013-06-27 |
| DK1715890T3 (da) | 2008-11-17 |
| AU2005212371B2 (en) | 2010-05-13 |
| CN101884789A (zh) | 2010-11-17 |
| HK1095762A1 (en) | 2007-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2006298A3 (en) | Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof | |
| BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
| PT1715890E (pt) | Ctgf como alvo para a terapia de microalbuminúria em doentes com nefropatia diabética | |
| WO2009050506A3 (en) | Combination 059 | |
| HRP20130707T1 (en) | Compositions and uses for treating multiple sclerosis | |
| WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
| TW200740804A (en) | Glucokinase activators | |
| ATE521608T1 (de) | Glucokinaseaktivatoren | |
| SI1615952T1 (sl) | Metoda zdravljenja vnetnih bolezni z uporabo specifičnih veznih sredstev humanega angiopoetin | |
| CR8380A (es) | Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos | |
| SG170775A1 (en) | 2 -aminopyridine analogs as glucokinase activators | |
| WO2010059969A3 (en) | Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer | |
| CY1112397T1 (el) | Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου | |
| TW200509892A (en) | Novel aminobenzophenone compounds | |
| GB2442915B (en) | Perylenequinone derivatives and uses thereof | |
| WO2005082386A3 (en) | Manganese and iron based compounds for elastogenesis and connective tissue treatment | |
| WO2006117660A3 (en) | Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins | |
| GB0416508D0 (en) | Therapeutic agents | |
| WO2004004653A3 (en) | Methods for treating psychosis associated with interferon-alpha therapy | |
| WO2006128125A3 (en) | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases | |
| MX2007013834A (es) | Terapias de enfermedades vasculares. | |
| SI1596879T1 (sl) | Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice | |
| GB0410238D0 (en) | Therapeutic agents | |
| MXPA05013975A (es) | Tratamiento de enfermedades asociadas con amiloide y epileptogenesis. | |
| WO2006004774A3 (en) | Laulimalide analogues as therapeutic agents |